Trial reportThe Journal of biological chemistry2014
Bet v 1 from birch pollen is a lipocalin-like protein acting as allergen only when devoid of iron by promoting Th2 lymphocytes.
Trial report in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 64 citations in OpenAlex.
- Review
- Apoptotic BMSCs reduce grafted islets apoptosis through the holo-Lcn2/Slc22a17/FeStem cell research & therapy · 2026Article
- Lymph food to improve canine atopic dermatitis: a randomized, double-blinded, controlled trial in dogs with standard-care treatment.Frontiers in veterinary science · 2025Article
- Article
- Malnutrition and Allergies: Tipping the Immune Balance towards Health.Journal of clinical medicine · 2024Review
- Ferroptotic alveolar epithelial type II cells drive TCell death discovery · 2024Article
- The Acari Hypothesis, V: deciphering allergenicity.Frontiers in allergy · 2024Article
- Nutritional Provision of Iron Complexes by the Major Allergen Alt a 1 to Human Immune Cells Decreases Its Presentation.International journal of molecular sciences · 2023Article
- Birch pollen-The unpleasant herald of spring.Frontiers in allergy · 2023Review
- Binding to Iron Quercetin Complexes Increases the Antioxidant Capacity of the Major Birch Pollen Allergen Bet v 1 and Reduces Its Allergenicity.Antioxidants (Basel, Switzerland) · 2022Article
- Bet v 1 triggers antiviral-type immune signalling in birch-pollen-allergic individuals.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Article
- Secretory protein beta-lactoglobulin in cattle stable dust may contribute to the allergy-protective farm effect.Clinical and translational allergy · 2022Article
- Iron-Deficiency in Atopic Diseases: Innate Immune Priming by Allergens and Siderophores.Frontiers in allergy · 2022Review
- Lack of iron, zinc, and vitamins as a contributor to the etiology of atopic diseases.Frontiers in nutrition · 2022Review
- Gibberellin-regulated proteins: Emergent allergens.Frontiers in allergy · 2022Article
- One Health in allergology: A concept that connects humans, animals, plants, and the environment.Allergy · 2021Article
- Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease.Respiratory research · 2021Review
- Bovine Holo-Beta-Lactoglobulin Cross-Protects Against Pollen Allergies in an Innate Manner in BALB/c Mice: Potential Model for the Farm Effect.Frontiers in immunology · 2021Article
- Article
- Ligand Binding of PR-10 Proteins with a Particular Focus on the Bet v 1 Allergen Family.Current allergy and asthma reports · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
It is hypothesized that allergens are at the borderline of self and non-self and, through as yet elusive circumstances, mount a Th2 response for allergic sensitization. The major birch pollen allergen Bet v 1 is considered the prototype for the PR-10 protein family causing respiratory allergy. Here, we give structural evidence that Bet v 1 is a lipocalin-like protein with a striking structural resemblance to human lipocalin 2. Lipocalin 2 is highly expressed in the lung where it exerts immunoregulatory functions dependent on being loaded with siderophore-bound iron (holo-form) or not (apo-form). We demonstrate that similar to lipocalin 2, Bet v 1 is capable of binding iron via catechol-based siderophores. Thereby, calculated Kd values of 66 nm surpassed affinities to known ligands nearly by a power of 10. Moreover, we give functional evidence of the immunomodulatory capacity of Bet v 1 being dependent on its iron-loaded state. When incubated to human immune cells, only the apo-form of Bet v 1, but not the holo-form, was able to promote Th2 cells secreting IL13. These results provide for the first time a functional understanding on the allergenicity of Bet v 1 and a basis for future allergen immunotherapies counteracting Th2 immune responses on a molecular basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.